Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on March 11, 2021. The filing serves to announce financial results for the fourth quarter and the full year ended December 31, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cincinnati, OH.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No material changes or comparative financial data are detailed in the body of this 8-K filing. The document solely acts as a notification that the results for the period ended December 31, 2020, have been announced.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are enumerated in the text provided.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Aerpio Pharmaceuticals, Inc. (Ticker: ARPO), not Whitehawk Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K summary text.
- Confirm the reporting period covers Q4 and the full year ended December 31, 2020.
- Note the company's status as an emerging growth company on the Nasdaq Capital Market.